21st Jun 2016 06:46
LONDON (Alliance News) - Summit Therapeutics PLC Tuesday presented further clinical trial data showing that its antibiotic ridinilazole outperformed the standard of care in preserving the gut microbiome of patients during the treatment of clostridium difficile infection.
This data was taken from a phase II trial of ridinilazole, and was presented at the ASM Microbe 2016 conference in Boston.
In the phase II trial ridinilazole demonstrated a "substantial clinical benefit" over the standard of care, vancomycin, including a large material reduction in recurrent disease.
Recurrence is a major issue in the management of clostridium difficile infection, and is promoted by disruption of the gut microbiome in patients, which occurs with treatments like vancomycin.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L